GABA-A receptor; anion channel
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats GABA-A receptor; anion channel as ChEMBL target CHEMBL1907607, mapped to UniProt O09028. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why GABA-A receptor; anion channel matters
GABA-A receptor; anion channel is reviewed as Gamma-aminobutyric acid receptor subunit pi (UniProt O09028); the current evidence base includes 28 approved drugs, 3354 compounds, and 548 assays, with lead potency reaching pChEMBL 10.3.
Gamma-aminobutyric acid receptor subunit pi Sequence length is 440 aa.
Review this target as GABA-A receptor; anion channel, mapped to UniProt O09028. ChEMBL maps the protein component as Gamma-aminobutyric acid receptor subunit pi. Sequence length is 440 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 28 approved drugs, 3354 compounds, and 548 assays for this target. The dominant activity type is IC50. CHEMBL380906 is the current potency anchor at pChEMBL 10.3.
Use CHEMBL380906 as the tractability anchor when discussing potency (pChEMBL 10.3).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why GABA-A receptor; anion channel matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt O09028, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL380906
|
10.3 | Ki | — |
|
|
No preferred name
CHEMBL3144615
|
10.3 | Ki | — |
|
|
No preferred name
CHEMBL3144841
|
10.1 | Ki | — |
|
|
No preferred name
CHEMBL54338
|
10.0 | Ki | — |
|
|
No preferred name
CHEMBL80436
|
10.0 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
ZURANOLONE
CHEMBL4105630
|
2023 |
|
|
GANAXOLONE
CHEMBL1568698
|
2022 |
|
|
BREXANOLONE
CHEMBL207538
|
2019 |
|
|
ZOLPIDEM
CHEMBL911
|
1992 |
|
|
FLUMAZENIL
CHEMBL407
|
1991 |
|
|
CLARITHROMYCIN
CHEMBL1741
|
1991 |
|
|
CIPROFLOXACIN
CHEMBL8
|
1987 |
|
|
NORFLOXACIN
CHEMBL9
|
1986 |
|
|
MIDAZOLAM
CHEMBL655
|
1985 |
|
|
ALPRAZOLAM
CHEMBL661
|
1981 |
|
|
TRIAZOLAM
CHEMBL646
|
1978 |
|
|
BACLOFEN
CHEMBL701
|
1977 |
|
|
CLONAZEPAM
CHEMBL452
|
1975 |
|
|
DIAZEPAM
CHEMBL12
|
1963 |
|
|
CHLORDIAZEPOXIDE
CHEMBL451
|
1960 |
|
|
ALPIDEM
CHEMBL54349
|
— |
|
|
ZOPICLONE
CHEMBL135400
|
— |
|
|
FLUNITRAZEPAM
CHEMBL13280
|
— |